跳至主要内容
临床试验/ITMCTR2100004448
ITMCTR2100004448招募中4 期

Efficacy of Bushen Huatan Decoction combined with Baduanjin in the treatment of polycystic ovary syndrome with insulin resistance (IR-PCOS), kidney deficiency and phlegm dampness: protocol for a randomized controlled pilot trial

Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

性别
Female

入选标准

  • (1) Chinese women aged from 18 to 35 years old.
  • (2) BMI over 25.0 kg/m2.
  • (3) Confirmed diagnosis of PCOS according to the 2003 Rotterdam criteria:
  • (a) irregular menstruation cycles (a periodic interval > 35 days or < 8 cycles in a year) or amenorrhea (a periodic interval > 90 days) or abnormal uterine bleeding;
  • (b) clinical manifestations of hyperandrogenism (hirsutism in mainland China is taken as Ferriman-Gallwey score >= 5) and/or hyperandrogenemia [free androgen index (FAI)=total testosterone (nmol/L)/SHBG (nmol/L) x 100 >4.5]; and
  • (c) transvaginal ultrasonography showing PCOM: the number of follicles with a diameter of 2-9 mm in one or both ovaries >= 12, and/or ovarian volume >= 10 ml [ovarian volume calculation: 0.5* long diameter (cm) * diameter (cm) * anteroposterior diameter (cm)]. Among all the above, (a) is a necessary condition, and matching one of (b) or (c) represents suspected PCOS, which then requires ruling out other factors and diseases that may cause hyperandrogenism and ovulation dysfunction.
  • (4) In line with the diagnosis criteria of TCM syndrome differentiation: kidney deficiency and phlegm dampness.
  • (5) Confirming the diagnosis of insulin resistance: the criteria of IR are defined according to the homeostatic model assessment of insulin resistance (HOMA-IR) [fasting plasma glucose (mmol/l) * fasting serum insulin (uIU/ml)/22.5]. A value >= 2.29 is considered to be indicative of IR.
  • (6) No history of using hormone drugs or drugs that affect glucose metabolism within the 3 months prior to treatment.
  • (7) Volunteer to participate in this trial and give informed consent.

排除标准

  • (1) Patients with any other endocrine diseases related to this disease (such as Cushing's syndrome, congenital adrenal hyperplasia, 21-hydroxylase deficiency, hyperprolactinemia, uncorrected thyroid disease, type 1 or type 2 diabetes mellitus, etc. ).
  • (2) Patients with congenital malformations or defects of the reproductive system, organic lesions of the reproductive system (such as uterine fibroids, ovarian cysts, etc. ).
  • (3) Patients with reproductive malignancies (such as endometrial cancer, cervical cancer, etc. ).
  • (4) Patients with genital inflammation, genital tuberculosis, and pelvic inflammatory disease.
  • (5) One of the spouses has a sexually transmitted disease such as syphilis and AIDS.
  • (6) Patients with serious primary diseases of the cardiovascular, cerebrovascular, liver, kidney and hematopoietic systems or psychoses.
  • (7) Patients with chromosomal abnormalities, pregnancy or lactation.
  • (8) Interventions of any other medication treatments, including hormone drugs, drugs that will affect glucose metabolism, Chinese herbal prescriptions or acupuncture in the previous 3 months.
  • (9) Patients allergic to the drugs used in this study.
  • (10) Patients in other clinical trials at the same time.

研究者

发起方
Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine

相似试验